338 related articles for article (PubMed ID: 12880487)
21. Formation and removal of alpha-synuclein aggregates in cells exposed to mitochondrial inhibitors.
Lee HJ; Shin SY; Choi C; Lee YH; Lee SJ
J Biol Chem; 2002 Feb; 277(7):5411-7. PubMed ID: 11724769
[TBL] [Abstract][Full Text] [Related]
22. Mitochondrial associated metabolic proteins are selectively oxidized in A30P alpha-synuclein transgenic mice--a model of familial Parkinson's disease.
Poon HF; Frasier M; Shreve N; Calabrese V; Wolozin B; Butterfield DA
Neurobiol Dis; 2005 Apr; 18(3):492-8. PubMed ID: 15755676
[TBL] [Abstract][Full Text] [Related]
23. Alpha-synuclein and Parkinson's disease.
Lücking CB; Brice A
Cell Mol Life Sci; 2000 Dec; 57(13-14):1894-908. PubMed ID: 11215516
[TBL] [Abstract][Full Text] [Related]
24. Targeting α-synuclein aggregation and its role in mitochondrial dysfunction in Parkinson's disease.
Haque ME; Akther M; Azam S; Kim IS; Lin Y; Lee YH; Choi DK
Br J Pharmacol; 2022 Jan; 179(1):23-45. PubMed ID: 34528272
[TBL] [Abstract][Full Text] [Related]
25. Synucleins and their relationship to Parkinson's disease.
von Bohlen Und Halbach O
Cell Tissue Res; 2004 Oct; 318(1):163-74. PubMed ID: 15503152
[TBL] [Abstract][Full Text] [Related]
26. Alpha-synuclein and the pathogenesis of Parkinson's disease.
Martin FL; Williamson SJ; Paleologou KE; Allsop D; El-Agnaf OM
Protein Pept Lett; 2004 Jun; 11(3):229-37. PubMed ID: 15182224
[TBL] [Abstract][Full Text] [Related]
27. Therapeutic strategies for Parkinson's disease based on data derived from genetic research.
Riess O; Berg D; Krüger R; Schulz JB
J Neurol; 2003 Feb; 250 Suppl 1():I3-10. PubMed ID: 12761628
[TBL] [Abstract][Full Text] [Related]
28. A protein-chameleon: conformational plasticity of alpha-synuclein, a disordered protein involved in neurodegenerative disorders.
Uversky VN
J Biomol Struct Dyn; 2003 Oct; 21(2):211-34. PubMed ID: 12956606
[TBL] [Abstract][Full Text] [Related]
29. alpha-Synuclein implicated in Parkinson's disease catalyses the formation of hydrogen peroxide in vitro.
Turnbull S; Tabner BJ; El-Agnaf OM; Moore S; Davies Y; Allsop D
Free Radic Biol Med; 2001 May; 30(10):1163-70. PubMed ID: 11369507
[TBL] [Abstract][Full Text] [Related]
30. Filamentous nerve cell inclusions in neurodegenerative diseases: tauopathies and alpha-synucleinopathies.
Goedert M
Philos Trans R Soc Lond B Biol Sci; 1999 Jun; 354(1386):1101-18. PubMed ID: 10434313
[TBL] [Abstract][Full Text] [Related]
31. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease.
Conway KA; Harper JD; Lansbury PT
Nat Med; 1998 Nov; 4(11):1318-20. PubMed ID: 9809558
[TBL] [Abstract][Full Text] [Related]
32. Both familial Parkinson's disease mutations accelerate alpha-synuclein aggregation.
Narhi L; Wood SJ; Steavenson S; Jiang Y; Wu GM; Anafi D; Kaufman SA; Martin F; Sitney K; Denis P; Louis JC; Wypych J; Biere AL; Citron M
J Biol Chem; 1999 Apr; 274(14):9843-6. PubMed ID: 10092675
[TBL] [Abstract][Full Text] [Related]
33. Parkinson's disease-associated alpha-synuclein is a calmodulin substrate.
Martinez J; Moeller I; Erdjument-Bromage H; Tempst P; Lauring B
J Biol Chem; 2003 May; 278(19):17379-87. PubMed ID: 12610000
[TBL] [Abstract][Full Text] [Related]
34. Protein misfolding and aggregation in Parkinson's disease.
Tan JM; Wong ES; Lim KL
Antioxid Redox Signal; 2009 Sep; 11(9):2119-34. PubMed ID: 19243238
[TBL] [Abstract][Full Text] [Related]
35. Pathogenic alpha-synuclein aggregates preferentially bind to mitochondria and affect cellular respiration.
Wang X; Becker K; Levine N; Zhang M; Lieberman AP; Moore DJ; Ma J
Acta Neuropathol Commun; 2019 Mar; 7(1):41. PubMed ID: 30871620
[TBL] [Abstract][Full Text] [Related]
36. Intramitochondrial proteostasis is directly coupled to α-synuclein and amyloid β1-42 pathologies.
Lautenschläger J; Wagner-Valladolid S; Stephens AD; Fernández-Villegas A; Hockings C; Mishra A; Manton JD; Fantham MJ; Lu M; Rees EJ; Kaminski CF; Kaminski Schierle GS
J Biol Chem; 2020 Jul; 295(30):10138-10152. PubMed ID: 32385113
[TBL] [Abstract][Full Text] [Related]
37. Αlpha-Synuclein as a Mediator in the Interplay between Aging and Parkinson's Disease.
Bobela W; Aebischer P; Schneider BL
Biomolecules; 2015 Oct; 5(4):2675-700. PubMed ID: 26501339
[TBL] [Abstract][Full Text] [Related]
38. Neurobiology of alpha-synuclein.
Vekrellis K; Rideout HJ; Stefanis L
Mol Neurobiol; 2004 Aug; 30(1):1-21. PubMed ID: 15247485
[TBL] [Abstract][Full Text] [Related]
39. Parkinson's disease: alpha-synuclein and parkin in protein aggregation and the reversal of unfolded protein stress.
Jakobsen LD; Jensen PH
Methods Mol Biol; 2003; 232():57-66. PubMed ID: 12840539
[No Abstract] [Full Text] [Related]
40. Is there a cause-and-effect relationship between alpha-synuclein fibrillization and Parkinson's disease?
Goldberg MS; Lansbury PT
Nat Cell Biol; 2000 Jul; 2(7):E115-9. PubMed ID: 10878819
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
